Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia

The study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of CD19 positive Relapsed or Refractory acute lymphoblastic leukemia.

Trial Details

NCT ID
NCT04684147
Phase
PHASE2
Sponsor
Juventas Cell Therapy Ltd.
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • single dose of CNCT19
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Chongqing, Chongqing Municipality, China|29.56026,106.55771
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Sanhe, Hebei, China|39.98049,117.06887
  • Zhengzhou, Henan, China|34.75778,113.64861

Key Eligibility Criteria

  • Informed consent is signed by the subject.
  • Age 18 to 65.
  • Relapsed or refractory acute lymphoblastic leukemia (ALL). (1) Relapse within 12 months of first remission; (2)a. Without remission after more than…
  • Documentation of CD19 tumor expression demonstrated in bone marrow or peripheral blood within 3 months of study entry.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →